ASCO结直肠癌研究进展精粹

2016ASCO结直肠癌研究精粹良医汇-肿瘤资讯Impactofprimarytumorlocationon<br/>OverallSurvivalandProgressionFreeSurvival<br/>inpatientswithmetastaticcolorectalcancer:<br/>AnalysisofCALGB/SWOG80405(Alliance)PresentedByAlanVenookat2016ASCOAnnualMeeting CALGB/SWOG80405 PresentedByAlanVenookat2016ASCOAnnualMeeting CALGB/SWOG80405 PresentedByAlanVenookat2016ASCOAnnualMeetingSlide4PresentedByAlanVenookat2016ASCOAnnualMeetingEmbryology:TheoriginofthecolonPresentedByAlanVenookat2016ASCOAnnualMeetingSlide6PresentedByAlanVenookat2016ASCOAnnualMeetingCALGB80405:Sideofprimarytumor<br/>MethodsPresentedByAlanVenookat2016ASCOAnnualMeetingSlide8PresentedByAlanVenookat2016ASCOAnnualMeetingPatientCharacteristicsbyTumorSide,80405(KRASwt)PresentedByAlanVenookat2016ASCOAnnualMeeting80405:OverallSurvivalbySidednessPresentedByAlanVenookat2016ASCOAnnualMeeting80405:OSbySidedness(Bevacizumab)<br/>PresentedByAlanVenookat2016ASCOAnnualMeeting80405:OSbySidedness(Cetuximab)<br/>PresentedByAlanVenookat2016ASCOAnnualMeeting80405:SidednessisPrognostic<br/>ProgressionFreeSurvival(PFS)PresentedByAlanVenookat2016ASCOAnnualMeeting80405:SidednessisPrognostic<br/>OverallSurvival(OS)PresentedByAlanVenookat2016ASCOAnnualMeetingSlide15PresentedByAlanVenookat2016ASCOAnnualMeetingMedianOSbySidedness:<br/>80405andFIRE-3*PresentedByAlanVenookat2016ASCOAnnualMeeting80405:SidednessPredictiveforBiologics<br/>Biologicby1°SideInteractionPresentedByAlanVenookat2016ASCOAnnualMeetingOverallSurvivalbySidednessandBiologicPresentedByAlanVenookat2016ASCOAnnualMeetingOSbyBiologic<br/>Right-sidedprimaryPresentedByAlanVenookat2016ASCOAnnualMeetingOSbyBiologic<br/>Left-sidedprimaryPresentedByAlanVenookat2016ASCOAnnualMeetingCALGB/SWOG80405:<br/>SidednessinKRASwtmCRCPresentedByAlanVenookat2016ASCOAnnualMeeting<br/>SidednessinmCRC:BiologicalsurrogatePresentedByAlanVenookat2016ASCOAnnualMeeting<br/> CorrelativeStudies<br/>Tumor/Plasma/Serum>44000samples<br/>PresentedByAlanVenookat2016ASCOAnnualMeetingCALGB/SWOG80405:LimitationsPresentedByAlanVenookat2016ASCOAnnualMeeting80405:SidednessPrognosticinKRASmutpatients<br/>(KRASmutantpts,pre-amendmentcohort)PresentedByAlanVenookat2016ASCOAnnualMeeting80405:ExploratoryAnalysis(wtvmut)<br/>PresentedByAlanVenookat2016ASCOAnnualMeetingSidednessinmCRC:TakeHomeMessagesPresentedByAlanVenookat2016ASCOAnnualMeetingStayTuned:<br/>NextthreepresentationsPresentedByAlanVenookat2016ASCOAnnualMeetingSidednessinmCRCPresentedByAlanVenookat2016ASCOAnnualMeetingACKNOWLEDGEMENTSPresentedByAlanVenookat2016ASCOAnnualMeetingTHANKYOUPresentedByAlanVenookat2016ASCOAnnualMeetingRachelPearline,MD,MPH<br/>inmemorium:1977-2015PresentedByAlanVenookat2016ASCOAnnualMeetingSlide33PresentedByAlanVenookat2016ASCOAnnualMeetingNCI9673:AMulti-InstitutionalETCTNPhaseIIStudyofNivolumabinRefractoryMetastaticSquamousCellCarcinomaoftheAnalCanal(SCCA)PresentedByVanMorrisat2016ASCOAnnualMeetingDisclosureInformation<br/>RelationshipswithpaniesPresentedByVanMorrisat2016ASCOAnnualMeetingIncidenceofAnalCancerPresentedByVanMorrisat2016ASCOAnnualMeetingRationaleforNivolumabinMetastaticSCCA:PresentedByVanMorrisat2016ASCOAnnualMeetingSalientFactsofAnalCancerPresentedByVanMorrisat2016ASCOAnnualMeeting2016NGuidelinesforMetastaticAnalCancerPresentedByVanMorrisat2016ASCOAnnualMeetingNCI9673:PhaseIIDesignofNivolumabinMetastaticSCCAPresentedByVanMorrisat2016ASCOAnnualMeetingObjectivesofNCI9673:PresentedByVanMorrisat2016ASCOAnnualMeetingInclusionCriteria:PresentedByVanMorrisat2016ASCOAnnualMeetingNCI9673:ConsortDiagramPresentedByVanMorrisat2016ASCOAnnualMeetingStudyDesign:PseudoprogressionPresentedByVanMorrisat2016ASCOAnnualMeetingPatientDemographicsPresentedByVanMorrisat2016ASCOAnnualMeetingPrimaryEndpoint:ResponseRatePresentedByVanMorrisat2016ASCOAnnualMeetingNCI9673:PrimaryEndpointofResponseRatePresentedByVanMorrisat2016ASCOAnnualMeetingSecondaryEndpoint:PresentedByVanMorrisat2016ASCOAnnualMeetingPatient#1:PresentedByVanMorrisat2016ASCOAnnualMeetingPatient#2:PresentedByVanMorrisat2016ASCOAnnualMeetingNCI9673ToxicitiesofTherapyPresentedByVanMorrisat2016ASCOAnnualMeetingSlide19PresentedByVanMorrisat2016ASCOAnnualMeetingSlide20PresentedByVanMorrisat2016ASCOAnnualMeetingSlide21PresentedByVanMorrisat2016ASCOAnnualMeetingConclusions:PresentedByVanMorrisat2016ASCOAnnualMeetingExperimentalTherapeuticClinicalTrialsNetwork(ETCTN)NCI/CTEPSitesPresentedByVanMorrisat2016ASCOAnnualMeetingFutureDirectionsforMetSCCAPresentedByVanMorrisat2016ASCOAnnualMeetingAcknowledgements:PresentedByVanMorrisat2016ASCOAnnualMeetingThankyouforyourattention!PresentedByVanMorrisat2016ASCOAnnualMeetingClinicalactivityandsafetyofcobimetinibandatezolizumabincolorectalcancerPresentedByJohannaBendellat2016ASCOAnnualMeetingColorectalCancer:UnmetNeedPresentedByJohannaBendellat2016ASCOAnnualMeetingSlide3PresentedByJohannaBendellat2016ASCOAnnualMeetingAtezolizumab:AnAnti-PDL1AntibodyPresentedByJohannaBendellat2016ASCOAnnualMeetingPD-L1andMEKInhibition:ARationalbinationPresentedByJohannaBendellat2016ASCOAnnualMeetingPhaseIbDoseEscalationandCohortExpansionStudy(NCT01988896)PresentedByJohannaBendellat2016ASCOAnnualMeetingPhaseIbDoseEscalationandCohortExpansionStudy(NCT01988896)PresentedByJohannaBendellat2016ASCOAnnualMeetingBaselineCharacteristicsPresentedByJohannaBendellat2016ASCOAnnualMeetingBaselineCharacteristics(cont.)PresentedByJohannaBendellat2016ASCOAnnualMeetingSafetySummaryPresentedByJohannaBendellat2016ASCOAnnualMeetingSafety:Treatment-relatedAEsPresentedByJohannaBendellat2016ASCOAnnualMeetingEfficacy:ConfirmedObjectiveResponsePresentedByJohannaBendellat2016ASCOAnnualMeetingEfficacy:ChangeinTumorBurdenPresentedByJohannaBendellat2016ASCOAnnualMeetingEfficacy:ChangeinTumorBurdenOverTimePresentedByJohannaBendellat2016ASCOAnnualMeetingEfficacy:DurationofTreatmentandResponsePresentedByJohannaBendellat2016ASCOAnnualMeetingEfficacy:Progression-FreeSurvivalAndOverallSurvivalPresentedByJohannaBendellat2016ASCOAnnualMeetingBiomarkers:CD8T-cellAccumulationandMHCIExpressionPresentedByJohannaBendellat2016ASCOAnnualMeetingSummaryPresentedByJohannaBendellat2016ASCOAnnualMeetingSummaryPresentedByJohannaBendellat2016ASCOAnnualMeetingAcknowledgmentsPresentedByJohannaBendellat2016ASCOAnnualMeetingSlide1PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide2PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide3PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide4PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide5PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide6PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide7PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide8PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide9PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide10PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide11PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide12PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide13PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide14PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide15PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide16PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide17PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide18PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide19PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide20PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide21PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide22PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide23PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide24PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide25PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide26PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide27PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide28PresentedByJeromeGalonat2016ASCOAnnualMeetingSlide29PresentedByJeromeGalonat2016ASCOAnnualMeetingNivolumab±IpilimumabinTreatmentofPatientsWithMetastaticColorectalCancerWithandWithoutHighMicrosatelliteInstability:<br/>CheckMate142InterimResultsPresentedByMichaelOvermanat2016ASCOAnnualMeetingDisclosurePresentedByMichaelOvermanat2016ASCOAnnualMeetingIntroduction<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingHypermutationandImmuno-Oncology:<br/>RationaleforEvaluatingNivolumab±IpilimumabinCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingIpilimumabandNivolumab<br/>MechanismsofActionPresentedByMichaelOvermanat2016ASCOAnnualMeetingEligibilityCriteria<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingPhase2CheckMate142StudyDesign:MicrosatelliteStable(MSS)CohortPresentedByMichaelOvermanat2016ASCOAnnualMeetingPhase2CheckMate142StudyDesign:<br/>MSI-HCohortPresentedByMichaelOvermanat2016ASCOAnnualMeetingStudyEndpoints<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingDemographics<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingDiseaseCharacteristicsandPriorTherapy<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingMSI-HPatientDisposition<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingInvestigator-AssessedBestOverallResponsein<br/>PatientsWithMSI-HReceivingNivolumabMonotherapyPresentedByMichaelOvermanat2016ASCOAnnualMeetingInvestigator-AssessedBestOverallResponsein<br/>PatientsWithMSI-HReceivingNivolumab+IpilimumabPresentedByMichaelOvermanat2016ASCOAnnualMeetingBestReductioninTargetLesionSize<br/>inPatientsWithMSI-HPresentedByMichaelOvermanat2016ASCOAnnualMeetingInvestigator-AssessedPFSinPatientsWithMSI-H<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingOSinPatientsWithMSI-H<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeeting<br/>SummaryofEfficacyinPatientsWithMSS<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingTreatment-RelatedAdverseEvents<br/>in≥15%ofPatientsWithMSI-HPresentedByMichaelOvermanat2016ASCOAnnualMeetingTreatment-RelatedAdverseEvents<br/>in≥15%ofPatientsWithMSSPresentedByMichaelOvermanat2016ASCOAnnualMeetingConclusions<br/>Nivolumab±IpilimumabinMetastaticCRCPresentedByMichaelOvermanat2016ASCOAnnualMeetingAcknowledgmentsPresentedByMichaelOvermanat2016ASCOAnnualMeetingCheckMate142InvestigatorsPresentedByMichaelOvermanat2016ASCOAnnualMeetingImmunotherapyBeyond(andincluding)MicrosatelliteInstabilityPresentedByNeilSegalat2016ASCOAnnualMeetingOutline:PresentedByNeilSegalat2016ASCOAnnualMeetingPhaseI/IIstudybyOvermanetal.:MSI-HcohortsPresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingSlide8PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingPhaseIbstudybyBendelletal.PresentedByNeilSegalat2016ASCOAnnualMeetingSlide12PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplicationsPresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplicationsPresentedByNeilSegalat2016ASCOAnnualMeetingSafetyresultsPresentedByNeilSegalat2016ASCOAnnualMeetingSlide16PresentedByNeilSegalat2016ASCOAnnualMeetingSlide17PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingETCTNphaseIIstudybyEngetal.(analcancer)PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplications:PresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplicationsPresentedByNeilSegalat2016ASCOAnnualMeetingTheimmunoscorestudyPresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplicationsPresentedByNeilSegalat2016ASCOAnnualMeetingStudyimplicationsPresentedByNeilSegalat2016ASCOAnnualMeetingNextstepsPresentedByNeilSegalat2016ASCOAnnualMeetingTakehomepointsPresentedByNeilSegalat2016ASCOAnnualMeetingThankyouforyourattentionPresentedByNeilSegalat2016ASCOAnnualMeetingTheCRESTTrialPresentedByJamesHillat2016ASCOAnnualMeetingLearningObjectivesforobstructingcolorectalcancerPresentedByJamesHillat2016ASCOAnnualMeetingRationaleofCREST–ConvertingemergencyintoelectivesurgeryPresentedByJamesHillat2016ASCOAnnualMeetingSelf-expandablemetalstentsforobstructingcolonicandextracoloniccancer: